Anal Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 20 – Jul 27, 2026
Personalising radiotherapy dose in anal cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trials.
RADIOTHER ONCOL · Q1 JOURNAL - RANK #22/212
This study reports 6-month patient-reported outcomes from the PLATO platform of three prospective clinical trials in anal squamous cell carcinoma: ACT3 (adjuvant chemoradiotherapy vs observation after local excision), ACT4 (reduced- vs standard-dose chemoradiotherapy), and ACT5 (three dose-escalated chemoradiotherapy regimens). PROs (EORTC QLQ-C30 and QLQ-ANL27) were collected at multiple time points with >10-point mean score differences deemed clinically relevant; 709 patients were enrolled (706 mITT) across 36 UK sites, PRO consent was 98.9% and 6-month completion 86.0%. ACT5 patients had worse baseline function/symptoms; all treated groups showed large declines at end of treatment with most returning to baseline by 6 months, though ACT5 had persistent bowel deficits and ACT4 standard-dose and ACT5 reported poorer sexual function at 6 months. The authors conclude risk-adapted radiotherapy dosing is feasible with excellent PRO compliance, and longer follow-up will define late effects.
10.1016/j.radonc.2026.111706